This study investigated the diagnostic utility of plasma phosphorylated tau (p-tau) at threonine-212 (p-tau212) as a biomarker for Alzheimer's disease (AD). A novel blood-based immunoassay specific to p-tau212 was developed and tested in multiple cohorts. Results showed high diagnostic performance for AD diagnosis and detection of amyloid and tau pathology, comparable to p-tau217 but superior to p-tau181 and p-tau231. Immunohistochemical staining confirmed p-tau212 presence in neurofibrillary tangles. Plasma p-tau212 is a promising peripheral biomarker for AD.
Publisher
Nature Communications
Published On
Mar 23, 2024
Authors
Przemysław R. Kac, Fernando González-Ortiz, Andreja Emeršič, Maciej Dulewicz, Srinivas Koutarapu, Michael Tront, Yang An, Denis Smirnov, Agnieszka Kułczyńska-Przybik, Vijay R. Varma, Nicholas J. Ashton, Laia Montoliu-Gaya, Elena Camporesi, Izabela Winkel, Bogusław Paradowski, Abhay Moghekar, Juan C. Tronosco, Tammaryn Lashley, Gunnar Brinkmalm, Susan M. Resnick, Barbara Mroczko, Hlin Kvartsberg, Milica Gregorić Kramberger, Jörg Haeusler, Saša Čučnik, Peter Harrison, Henrik Zetterberg, Piotr Lewczuk, Madhav Thambisetty, Uroš Rot, Doulin Galasrok, Kai Blennow, Thomas K. Karikari
Tags
Alzheimer's disease
biomarker
plasma phosphorylated tau
diagnostic performance
immunoassay
neurofibrillary tangles
tau pathology
Related Publications
Explore these studies to deepen your understanding of the subject.
